Market Intelligence, Clinical Progress, and High-Purity Reagents for Neurological, Endocrine, and Cardiovascular Drug Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for CACNA1D drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CACNA1D Domain & Loop Proteins / ECD / Mutant Fragments (TM5-TM6). High purity (>95%), Endotoxin <1 EU/µg, Sequence Verified. HEK293 Expressed. | View CACNA1D Products |
| Gene Delivery | CACNA1D Lentivirus Premade Particles (Full-length ORF). Sequence Verified, Endotoxin Controlled. For stable cell lines with native conformation. | View CACNA1D Products |
| Benchmark Ab | Anti-CACNA1D Recombinant Antibody / Selective Scaffold. Sequence-verified positive control for Western blot, ICC, and selectivity screening. | View CACNA1D Products |
| Validator | CACNA1D siRNA Set (3 unique sequences). For knockdown verification in calcium flux and patch-clamp assays. Endotoxin controlled. | View CACNA1D Products |
| Related Target A: CACNA1C | CACNA1C (Cav1.2) – Closest L-type homolog; essential for selectivity screening and cardiac off-target profiling. | View CACNA1C Products |
| Related Target B: CACNA1S | CACNA1S (Cav1.1) – Skeletal muscle L-type channel; critical for muscle toxicity counter-screening. | View CACNA1S Products |
| Related Target C: KCNJ5 | KCNJ5 (GIRK4) – Potassium channel synergistically involved in aldosterone-producing adenomas; companion diagnostic target. | View KCNJ5 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Native Conformation & Membrane Topology | Lentivirus-mediated stable expression in mammalian cells; preserves post-translational modifications and channel topology for electrophysiology. |
| Cav1.3 vs Cav1.2 Selectivity (Cardiac Safety) | Human CACNA1D/CACNA1C ortholog protein panels (>95% purity) and stable cell lines for selectivity assays. |
| Knockdown Verification & False-Positive Control | Validated siRNA with endotoxin <0.1 EU/µg for specificity checks in calcium imaging and patch-clamp. |
| Binding Assay Standardization & Kinetics | High-purity recombinant extracellular loop proteins for SPR / BLI / ELISA; endotoxin controlled. |
| Pathological Mutant Screening | Aldosteronism-associated mutants (G403R, I770M) verified by mass spectrometry; available as recombinant fragments for mechanism studies. |
| Cross-Species Translational Assay | Human / Cynomolgus / Mouse ortholog proteins available; sequence verified for IND-enabling studies. |
Live CACNA1D R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CACNA1D-selective therapeutics is intensifying as the limitations of pan-L-type calcium channel blockers become clear. First-generation dihydropyridines inhibit both Cav1.2 and Cav1.3, producing unwanted cardiac inotropy and vascular effects. The next wave of R&D is targeting state-dependent allosteric modulators and highly selective small molecules for primary aldosteronism, resistant hypertension, Parkinson's disease, and neurodevelopmental disorders. Drug-resistant mutations (e.g., G403R, I770M) and combination therapies with potassium channel modulators (KCNJ5) are emerging frontiers. As pipelines mature, the critical bottleneck has shifted from target validation to molecular selectivity and assay standardization, driving demand for high-fidelity cell-based assays and isoform-specific reagents.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (Selective Antagonist) | Bayer AG, Northwestern Univ, Academic Consortia | Parkinson's Disease, Primary Aldosteronism, Resistant Hypertension, Depression | Isoform Selectivity Assay (Need CACNA1D vs CACNA1C stable cell lines + recombinant domains) |
| RNAi / ASO | Academic Consortia | Primary Aldosteronism, Autism | Knockdown Validation (Need highly accurate sequence-verified siRNA) |
| Peptide / Biologic Modulator | Specialized Biotech, Emerging Startups | Chronic Pain, Neuropathic Pain, Neuroprotection | Binding Affinity Validation (Need high-purity extracellular loop peptides) |
| Gene Diagnostic | Precision Medicine Labs | Resistant Hypertension, Adrenal Adenoma | Mutant vs WT Protein Panels (G403R, I770M validation) |